好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Standardized Inpatient Telestroke to Improve Access to Stroke Specialists
Cerebrovascular Disease and Interventional Neurology
P12 - Poster Session 12 (11:45 AM-12:45 PM)
14-015

To study the impact of standard-of-care inpatient telestroke evaluation on transfer rates and stroke specialist access.


Of 800,000 strokes per year in the United States, approximately 25% are recurrent. Stroke specialist evaluation with targeted secondary prevention reduces recurrent stroke risk, but access is limited, especially in rural areas. We evaluated feasibility of inpatient telestroke consultation to reduce transfer rates and increase stroke specialist evaluation rates for AIS patients within our telestroke network.


We assessed AIS care at five “spoke” hospitals between 1/1/21–12/31/23. Pre-intervention, all hospitals had telestroke coverage in emergency departments, protocolized stroke admission order sets, and stroke specialists at the “hub” available to provide guidance 24/7 via telephone consultation and chart review. Inpatient telestroke consultation by stroke specialists at the hub site was implemented sequentially in a phased rollout. Telestroke specialists guided the diagnostic stroke evaluation and secondary stroke prevention. A multivariable logistic regression model incorporating the stepped-wedge cluster design was utilized to  compare  rates of transfer and access to a stroke specialist pre- and post-intervention.

1,295 total AIS patients were included (537 and 758 pre- and post-inpatient telestroke implementation, respectively, median age 75.24 [IQR: 64.45-86.11], 47.7% female, 92.2% white, and median NIHSS 2 [IQR:0-5]). Transfer rates pre- and post-inpatient telestroke implementation were 58.5% and 37.5%, (adjusted p-value<0.01). Within specific transfer indications, stroke specialist evaluation (7.4% vs 0.9%) and higher level stroke center (27.6% vs 18.3%) showed the most absolute reduction. Stroke specialist consultation rate increased from 80.2% to 96.4% (adjusted p-value < 0.01). Similarly, stroke consultation became increasingly comprehensive (full telestroke consultation 1.4% versus 94.1%).

Inpatient telestroke consultation significantly increased access to stroke specialist consultation and decreased AIS transfer rates. This stroke care delivery model was feasible and could help address stroke healthcare disparities in underserved areas.
Authors/Disclosures
Karen S. Stalin (University of Minnesota)
PRESENTER
Ms. Stalin has nothing to disclose.
Pramit Jagtap Mr. Jagtap has nothing to disclose.
Beatriz Pereira Rios, MD Dr. Pereira Rios has nothing to disclose.
Maulik Lathiya, MBBS Dr. Lathiya has nothing to disclose.
Samuel Boes Mr. Boes has nothing to disclose.
Solmaz Ramezani Hashtjin, MD Dr. Ramezani Hashtjin has nothing to disclose.
Tanvi Mehta, BA Ms. Mehta has nothing to disclose.
Deborah Pestka Deborah Pestka has nothing to disclose.
Michael Usher No disclosure on file
Chloe Botsford, MPH Ms. Botsford has nothing to disclose.
Joseph Koopmeiners No disclosure on file
Timothy Beebe (University of Minnesota School of Public Health) The institution of Timothy Beebe has received research support from NIH. The institution of Timothy Beebe has received research support from AHRQ.
Genevieve Melton-Meaux Genevieve Melton-Meaux has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for American college of surgeons. Genevieve Melton-Meaux has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for University of Utah, Ohio state university, and Washington University. Genevieve Melton-Meaux has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for American medical informatics association. The institution of Genevieve Melton-Meaux has received research support from NIH, AHRQ, PCORI, FDA.
Christopher Streib, MD (Department of Neurology) Dr. Streib has nothing to disclose.